Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise

Sackner, Marvin A.; Gummels, Emerance; Adams, José A.

doi:10.1016/j.mehy.2004.01.025

Cited by 29 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-depressants, NSAIDs, anxiolytic drugs, stimulants, anti-allergy drugs and anti-hypotensive drugs have all been used, but are not universally beneficial [26]. The lack of effective therapy has led to use of plant extracts [27], homeopathy [28], [29], hypnosis [30], acupuncture [31], and whole body periodic acceleration stress [32], none with sustained benefits. The only modalities of treatment that have any proven benefits are cognitive behavioral therapy and graded exercise programs, both of which appear to aid by improving coping skills rather than reduce symptoms [33].…”

Section: Discussionmentioning

confidence: 99%

Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome

et al. 2010

View full text Add to dashboard Cite

BackgroundXenotropic murine leukemia-related retrovirus (XMRV) is a recently discovered retrovirus that has been linked to human prostate cancer and chronic fatigue syndrome (CFS). Both diseases affect a large fraction of the world population, with prostate cancer affecting one in six men, and CFS affecting an estimated 0.4 to 1% of the population.Principal FindingsForty-five compounds, including twenty-eight drugs approved for use in humans, were evaluated against XMRV replication in vitro. We found that the retroviral integrase inhibitor, raltegravir, was potent and selective against XMRV at submicromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and prostate cancer cell line, respectively. Another integrase inhibitor, L-000870812, and two nucleoside reverse transcriptase inhibitors, zidovudine (ZDV), and tenofovir disoproxil fumarate (TDF) also inhibited XMRV replication. When combined, these drugs displayed mostly synergistic effects against this virus, suggesting that combination therapy may delay or prevent the selection of resistant viruses.ConclusionsIf XMRV proves to be a causal factor in prostate cancer or CFS, these discoveries may allow for rational design of clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The failure of conventional therapies to provide adequate relief from the symptoms of CFS has led sufferers to experiment with various alternative therapies with markedly differing outcomes (Tharakan and Manyam, 2006;Gregg, 1997;Sekiya et al, 2005;Mears, 2005;Sackner et al, 2004;Weatherley-Jones et al, 2004;Ernst, 2004).…”

Section: Non-specific Therapiesmentioning

confidence: 99%

Chronic fatigue syndrome

Devanur

Kerr

2006

Journal of Clinical Virology

131

101

View full text Add to dashboard Cite

“…The platform varies the frequency and intensity of acceleration in a controlled fashion, imparting periodic sinusoidal inertial forces (pGz) to the body that add pulses to the circulation as the body accelerates and decelerates. Subsequent studies in healthy human subjects (19,20), in patients (20,21), in whole animals in vivo (15,22), and in isolated vessels in vitro indicate that application of pGz results in the generation of eNO (15); consistent with these findings is the observation that the effects of pGz can be blocked by l-NAME (15). Furthermore, in vivo studies demonstrate that the pGz-induced release of eNO provides protection in different models of hemodynamic inflammation (17,23,24).…”

mentioning

confidence: 84%